---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003849"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T08:02:48.745225+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma gets SMC OK to escalate PH-762 dose in Phase 1b; no dose-limiting toxicities

## Summary
- Safety Monitoring Committee recommended dose escalation to next concentration after initial cohort.
- No dose-limiting toxicities or clinically relevant treatment-emergent adverse events observed.
- PH-762 intratumoral injections were well tolerated in the first dose cohort.
- Phase 1b trial (NCT06014086) targets cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma.

## SEC filing metadata
- accession: 0001683168-24-003849
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316824003849/0001683168-24-003849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316824003849/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003849
- JSON: https://secwatch.observer/filing/0001683168-24-003849.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003849.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.